IMCR
$30.93+0.36 (+1.18%)
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Recent News
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress?
If you are trying to figure out whether Immunocore Holdings is attractively priced or already reflecting its potential, you are in the right place for a clear valuation breakdown. The share price closed at US$32.30 recently, with a 10.0% return over the past year but a 39.5% decline over three years and a 4.4% decline year to date, which may point to shifting views on both opportunity and risk. Recent news flow around Immunocore has focused on its pipeline progress and partnerships, which...
Immunocore Q4 Earnings Call Highlights
Immunocore (NASDAQ:IMCR) executives highlighted continued commercial momentum for KIMMTRAK and progress across a diversified pipeline during the company’s fourth-quarter and full-year 2025 earnings call. Management emphasized that 2025 results reflected “consistent execution” and pointed investors t
Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Immunocore Holdings PLC (IMCR) reports a 29% revenue increase driven by KimTrack's success, while advancing its oncology and infectious disease programs.
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.